VYNE Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
VYNE and Yarrow Bioscience will merge, creating a Nasdaq-listed company focused on advancing YB-101, a first-in-class TSHR antibody for Graves' disease and TED. The combined entity is well-funded, with a strong investor syndicate and a cash runway into 2028.
-
The session highlighted advances in BET inhibitor development for autoimmune and inflammatory diseases, with two lead assets progressing through clinical trials. Repibresib targets vitiligo with a Phase IIb readout expected mid-year, while VYN202 is in Phase Ib for psoriasis, with results anticipated by year-end.
-
The conference highlighted progress on BET inhibitors for autoimmune diseases, with repibresib in phase II-B for vitiligo and VYN202 in phase I-B for psoriasis. Key differentiators include once-daily dosing and strong safety data. Results for both programs are expected in 2024–2025.
Fiscal Year 2024
-
The team is advancing two BET inhibitor assets: VYN-201, a topical therapy for vitiligo now in phase 2b after strong early results, and VYN-202, an oral BD2-selective inhibitor in phase 1a with proof-of-concept trials planned for psoriasis and RA. Cash reserves support operations through next year.